Experimental Cancer Genetics, The Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.
Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Br J Cancer. 2021 Jan;124(1):156-160. doi: 10.1038/s41416-020-01090-2. Epub 2020 Oct 7.
Brain metastases are a major cause of melanoma-related mortality and morbidity. We undertook whole-exome sequencing of 50 tumours from patients undergoing surgical resection of brain metastases presenting as the first site of visceral disease spread and validated our findings in an independent dataset of 18 patients. Brain metastases had a similar driver mutational landscape to cutaneous melanomas in TCGA. However, KRAS was the most significantly enriched driver gene, with 4/50 (8%) of brain metastases harbouring non-synonymous mutations. Hotspot KRAS mutations were mutually exclusive from BRAF, NRAS and HRAS mutations and were associated with a reduced overall survival from the resection of brain metastases (HR 10.01, p = 0.001). Mutations in KRAS were clonal and concordant with extracranial disease, suggesting that these mutations are likely present within the primary. Our analyses suggest that KRAS mutations could help identify patients with primary melanoma at higher risk of brain metastases who may benefit from more intensive, protracted surveillance.
脑转移是黑色素瘤相关死亡率和发病率的主要原因。我们对 50 名因内脏疾病扩散而首次接受脑部转移手术切除的患者的肿瘤进行了全外显子组测序,并在独立的 18 名患者数据集进行了验证。脑转移与 TCGA 中的皮肤黑色素瘤具有相似的驱动突变景观。然而,KRAS 是最显著富集的驱动基因,50 个脑转移中有 4 个(8%)存在非同义突变。热点 KRAS 突变与 BRAF、NRAS 和 HRAS 突变相互排斥,与脑转移切除后的总生存时间缩短相关(HR 10.01,p=0.001)。KRAS 突变是克隆性的,与颅外疾病一致,这表明这些突变很可能存在于原发性肿瘤中。我们的分析表明,KRAS 突变可以帮助识别具有更高脑转移风险的原发性黑色素瘤患者,这些患者可能受益于更密集、更持久的监测。